ANTI-IL-6R: Phase I/II data

Data from 28 patients in the Phase I portion of a double-blind, placebo-controlled, European Phase I/II trial showed that single doses of 0.3-6 mg/kg IV ALX-0061 were well tolerated and dose-dependent...